$OLMA insider trading
Over the last 12 months, Olema Pharmaceuticals insiders reported no purchases and 13 sales totaling $24.9M across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $24.9M 13 events
- Events · 12m
- 13 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 24, 2026 | Harmon CyrusD | ▼ Sale | 25,000 | $11.65 | $291K | -3.4% | 2 tranches |
| Mar 4, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER · O | ▼ Sale | 40,000 | $23.79 | $952K | -100% | 3 tranches |
| Jan 20, 2026 | Harmon CyrusD | ▼ Sale | 10,000 | $26.88 | $269K | -1.4% | — |
| Jan 15, 2026 | Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. · O | ▼ Sale | 103,822 | $28.7 | $3.0M | -42.6% | 2 tranches |
| Jan 14, 2026 | Harmon CyrusD | ▼ Sale | 3,489 | $29.12 | $102K | -0.5% | — |
| Jan 14, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF · O | ▼ Sale | 100,000 | $28.24 | $2.8M | -15.6% | 4 tranches |
| Jan 12, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF · O | ▼ Sale | 10,000 | $28.34 | $283K | -6.5% | indirect |
| Dec 23, 2025 | Zojwalla NaseemChief Medical Officer · O | ▼ Sale | 269,509 | $27.94 | $7.5M | -98.4% | 4 tranches |
| Dec 22, 2025 | Harmon CyrusD | ▼ Sale | 2,881 | $28.53 | $82K | -0.4% | late |
| Dec 19, 2025 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF · O | ▼ Sale | 51,000 | $30.46 | $1.6M | -8.5% | 3 tranches |
| Dec 19, 2025 | CLARK IAN TD | ▼ Sale | 264,800 | $29.73 | $7.9M | -100% | 3 tranches |
| Sep 18, 2025 | Harmon CyrusD | ▼ Sale | 5,000 | $8.23 | $41K | -4.1% | 2 tranches · indirect |
| Sep 18, 2025 | Harmon CyrusD | ▼ Sale | 20,000 | $8.18 | $164K | -2.6% | 2 tranches |
Every $OLMA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Olema Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $OLMA feed.